Related Experiment Videos
Effects of labetalol on left ventricular mass and function in hypertension--an assessment by serial echocardiography
Insights
Labetalol effectively reduced left ventricular hypertrophy in hypertensive patients. Echocardiographic measurements showed decreased left ventricular mass and wall thickness without impacting left ventricular function.
Area of Science:
- Cardiology
- Hypertension Research
- Pharmacology
Background:
- Essential hypertension is often associated with left ventricular hypertrophy (LVH).
- Assessing LVH and its regression is crucial for managing hypertensive cardiovascular risk.
- Labetalol is an alpha- and beta-receptor blocking agent used for blood pressure control.
Purpose of the Study:
- To evaluate the effect of labetalol on left ventricular mass and function in patients with essential hypertension.
- To determine if blood pressure control with labetalol leads to regression of echocardiographically determined left ventricular hypertrophy.
Main Methods:
- Serial echocardiographic (M-mode) assessments of left ventricular mass and function were performed.
- 10 patients with uncomplicated essential hypertension were studied before and after blood pressure control with labetalol.
- Measurements included left ventricular mass, interventricular septal thickness, and posterior wall thickness.
Main Results:
- Systolic blood pressure correlated significantly with left ventricular mass before treatment.
- Labetalol treatment significantly reduced left ventricular mass (P < 0.01) and wall thickness (P < 0.05).
- Left ventricular function indices remained unchanged throughout the 3-month treatment period.
Conclusions:
- Labetalol effectively reduces left ventricular hypertrophy in patients with essential hypertension.
- The observed regression of LVH occurs without adverse effects on left ventricular function in the short term.
- These findings have significant implications for the management of hypertensive patients with LVH.
Abstract:
We determined echocardiographic (M-mode) indices of left ventricular mass and function serially at 1-month intervals in 10 patients with uncomplicated mild or moderate essential hypertension, before and after adequate control of blood pressure with labetalol, a combined alpha- and beta-receptor blocking agent. Seven patients had pretreatment echocardiographic evidence of left ventricular hypertrophy with disproportionate septal thickness in 4. Systolic blood pressure in the untreated state correlated well (r = 0.96) with left ventricular mass but poorly (r = 0.30) with diastolic pressure. Following a satisfactory blood pressure reduction, achieved in all patients, left ventricular mass decreased from 240.5 +/- 71.1 g to 159.5 +/- 40.7 g (P less than 0.01), interventricular septal thickness from 1.33 +/- 0.3 cm to 0.92 +/- 0.25 cm (P less than 0.01) and posterior wall thickness from 1.03 +/- 0.23 cm to 0.93 +/- 0.23 cm (P less than 0.05). While the maximum changes in left ventricular mass were noted by the end of first month (P less than 0.01) with insignificant changes thereafter, the correlation of fall in blood pressure with change in left ventricular mass was significant only after 2 months of treatment (P less than 0.05). Indices of left ventricular function (end-diastolic volume, ejection fraction, fractional diameter shortening, left atrial dimension and posterior aortic wall motion) were normal before treatment and remained unchanged during 3 months of treatment. In this short-term study, labetalol reduced left ventricular hypertrophy (expressed as left ventricular mass and wall thickness) without altering left ventricular function indices in patients with uncomplicated essential hypertension. This has important implications in the treatment of hypertensive patients.